Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection - Ito, Wataru; Fukumori, Tatsuya; Asaoka, Nao; Imakita, Natsuko; Nishimura, Tomoko; Furukawa, Ryutaro; Nishihara, Yuji; Fujikura, Hiroyuki; Sekine, Takahiro; Yamaguchi, Naoki; Hirata, Yuichiro; Miyamoto, Sho; et al. (Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2024)
Keywords: Acalculous Cholecystitis - chemically induced; Acalculous Cholecystitis - drug therapy; Acalculous Cholecystitis - virology; Acute acalculous cholecystitis; Aged; Alanine - administration & dosage; Alanine - adverse effects; Alanine - analogs & derivatives; Alanine - therapeutic use; Antibodies, Monoclonal, Humanized; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; COVID-19 - complications; COVID-19 Drug Treatment; Gamma-glutamyl transpeptidase; Humans; Immunocompromised Host; Lymphoma; Lymphoma, Follicular - drug therapy; Male; Nirmatrelvir/ritonavir; Obinutuzumab; Persistent SARS-CoV-2 infection; Ritonavir - administration & dosage; Ritonavir - adverse effects; Ritonavir - therapeutic use; SARS-CoV-2; Persistent SARS-CoV-2 infection; Obinutuzumab; Nirmatrelvir/ritonavir; Acute acalculous cholecystitis; Gamma-glutamyl transpeptidase; Lymphoma